Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial
Related Experiment Video
Updated: Dec 4, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
1Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Background:
In the TNT trial of triple negative breast cancer (NCT00532727), germline BRCA1/2 mutations were present in 28% of carboplatin responders. We assessed quantitative measures of structural chromosomal instability (CIN) to identify a wider patient subgroup within TNT with preferential benefit from carboplatin over docetaxel.
Patients And Methods:
Copy number aberrations (CNAs) were established from 135 formalin-fixed paraffin-embedded primary carcinomas using Illumina OmniExpress SNP-arrays. Seven published [allelic imbalanced CNA (AiCNA); allelic balanced CNA (AbCNA); copy number neutral loss of heterozygosity (CnLOH); number of telomeric allelic imbalances (NtAI); BRCA1-like status; percentage of genome altered (PGA); homologous recombination deficiency (HRD) scores] and two novel [Shannon diversity index (SI); high-level amplifications (HLAMP)] CIN-measurements were derived. HLAMP was defined based on the presence of at least one of the top 5% amplified cytobands located on 1q, 8q and 10p. Continuous CIN-measurements were divided into tertiles. All nine CIN-measurements were used to analyse objective response rate (ORR) and progression-free survival (PFS).
Results:
Patients with tumours without HLAMP had a numerically higher ORR and significantly longer PFS in the carboplatin (C) than in the docetaxel (D) arm [56% (C) versus 29% (D), PHLAMP,quiet = 0.085; PFS 6.1 months (C) versus 4.1 months (D), Pinteraction/HLAMP = 0.047]. In the carboplatin arm, patients with tumours showing intermediate telomeric NtAI and AiCNA had higher ORR [54% (C) versus 20% (D), PNtAI,intermediate = 0.03; 62% (C) versus 33% (D), PAiCNA,intermediate = 0.076]. Patients with high AiCNA and PGA had shorter PFS in the carboplatin arm [3.4 months (high) versus 5.7 months (low/intermediate); and 3.8 months (high) versus 5.6 months (low/intermediate), respectively; Pinteraction/AiCNA = 0.027, Padj.interaction/AiCNA = 0.125 and Pinteraction/PGA = 0.053, Padj.interaction/PGA = 0.176], whilst no difference was observed in the docetaxel arm.
Conclusions:
Patients with tumours lacking HLAMP and demonstrating intermediate CIN-measurements formed a subgroup benefitting from carboplatin relative to docetaxel treatment within the TNT trial. This suggests a complex and paradoxical relationship between the extent of genomic instability in primary tumours and treatment response in the metastatic setting.
Insights
Patients with triple-negative breast cancer lacking high-level amplifications (HLAMP) and showing intermediate chromosomal instability (CIN) benefit more from carboplatin than docetaxel. This finding identifies a subgroup with improved outcomes in the TNT trial.
Area of Science:
- Oncology
- Genomics
- Cancer Research
Background:
- Germline BRCA1/2 mutations are found in 28% of carboplatin responders in triple-negative breast cancer (TNT trial).
- Structural chromosomal instability (CIN) was assessed to identify a broader patient subgroup benefiting from carboplatin over docetaxel.
Purpose of the Study:
- To identify a wider patient subgroup within the TNT trial who preferentially benefit from carboplatin over docetaxel.
- To assess quantitative measures of structural chromosomal instability (CIN) for treatment selection in triple-negative breast cancer.
Main Methods:
- Copy number aberrations (CNAs) were analyzed from 135 primary carcinomas using SNP-arrays.
- Nine CIN measurements, including novel high-level amplifications (HLAMP) and Shannon diversity index (SI), were derived and analyzed.
- CIN measurements were categorized into tertiles to correlate with objective response rate (ORR) and progression-free survival (PFS).
Main Results:
- Tumors without HLAMP showed higher ORR and significantly longer PFS with carboplatin versus docetaxel (PFS: 6.1 vs. 4.1 months).
- Intermediate levels of allelic imbalanced CNA (AiCNA) and telomeric allelic imbalances (NtAI) correlated with higher ORR in the carboplatin arm.
- High AiCNA and percentage of genome altered (PGA) were associated with shorter PFS in the carboplatin arm, but not the docetaxel arm.
Conclusions:
- Patients with tumors lacking HLAMP and intermediate CIN measurements represent a subgroup benefiting from carboplatin over docetaxel in the TNT trial.
- Genomic instability in primary tumors exhibits a complex relationship with treatment response in metastatic triple-negative breast cancer.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019